On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").

Simultaneously, the conceptual design of the common light chain library was also carried out. Our researchers discovered that the stability and compatibility of the light chain play a crucial role ...

Although both these forms of systemic amyloidosis are common, ATTRwt amyloidosis is more prevalent. Fibrillogenesis in immunoglobulin light chain (AL) amyloidosis is initiated from a small B-cell ...

and ImmuMab Light® mouse generating fully human common-light-chain antibody. ImmuHeavy® Rabbit is currently under construction to generate rabbit heavy-chain-only antibodies. By continuously ...

These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery ...

This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies ...

SHANGHAI, June 11, 2023 /PRNewswire/ -- On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody ...

SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred ...

This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, ...